Indivior Pharmaceuticals, Inc. Insider Trading

INDV

⊜ Compare

Last 12 months

Insiders bought 312K and sold $2.83M on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$2.52M

10 buys · 3 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

7 / 2

executives and directors

Last open-market buy

Aug 2026

Aug 27, 2026

Get an email when INDV's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 27	Woodrow D Anderson Chief Accounting Officer	Bought	1,500	$35.69	54K	5.7%	Form 4
Aug 5	Woodrow D Anderson Chief Accounting Officer	Bought	1,500	$36.28	54K	6.1%	Form 4
Jul 10	Christian Heidbreder Chief Scientific Officer	Sold10b5-1 plan	18,586	$41.14	765K	8.2%	Form 4
Jun 11	Christian Heidbreder Chief Scientific Officer	Sold10b5-1 plan	18,586	$38.06	707K	7.5%	Form 4
Jun 8	Ryan Preblick Chief Financial Officer	Sold10b5-1 plan	36,000	$37.70	$1.36M	11%	Form 4
Mar 13	Barbara Ryan Director	Bought	8	$31.09	$249	0.1%	Form 4
Mar 9	Barbara Ryan Director	Bought	31	$32.56	1K	0.5%	Form 4
Mar 6	Stuart A Kingsley Director	Bought	940	$31.87	30K	20%	Form 4
Jan 5	Keith Humphreys Director	Bought	775	$35.39	27K	15%	Form 4
Jan 5	Barbara Ryan Director	Bought	775	$35.39	27K	65%	Form 4
Jan 5	David E. Wheadon Director	Bought	1,771	$35.39	63K	14%	Form 4
Jan 5	Mark Stejbach Director	Bought	775	$35.39	27K	4.8%	Form 4
Jan 5	Daniel A Ninivaggi Director	Bought	775	$35.39	27K	4.8%	Form 4

Aug 27
Woodrow D Anderson
Chief Accounting Officer · bought 1,500 at $35.69
54K
5.7% of stake
Aug 5
Woodrow D Anderson
Chief Accounting Officer · bought 1,500 at $36.28
54K
6.1% of stake
Jul 1010b5-1 plan
Christian Heidbreder
Chief Scientific Officer · sold 18,586 at $41.14
765K
8.2% of stake
Jun 1110b5-1 plan
Christian Heidbreder
Chief Scientific Officer · sold 18,586 at $38.06
707K
7.5% of stake
Jun 810b5-1 plan
Ryan Preblick
Chief Financial Officer · sold 36,000 at $37.70
$1.36M
11% of stake
Mar 13
Barbara Ryan
Director · bought 8 at $31.09
$249
0.1% of stake
Mar 9
Barbara Ryan
Director · bought 31 at $32.56
1K
0.5% of stake
Mar 6
Stuart A Kingsley
Director · bought 940 at $31.87
30K
20% of stake
Jan 5
Keith Humphreys
Director · bought 775 at $35.39
27K
15% of stake
Jan 5
Barbara Ryan
Director · bought 775 at $35.39
27K
65% of stake
Jan 5
David E. Wheadon
Director · bought 1,771 at $35.39
63K
14% of stake
Jan 5
Mark Stejbach
Director · bought 775 at $35.39
27K
4.8% of stake
Jan 5
Daniel A Ninivaggi
Director · bought 775 at $35.39
27K
4.8% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch INDV, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with INDV

CompareIntrinsic value

MDGLMadrigal Pharmaceuticals, Inc.

$400.67+1.10%10

PAHCPhibro Animal Health Corporation

$39.43+4.73%57

PTCTPTC Therapeutics, Inc.

$68.97+1.25%65

ACADAcadia Pharmaceuticals Inc.

$21.49+4.47%74

INSMInsmed Inc.

$110.00+5.32%40

APLSApellis Pharmaceuticals, Inc.

$3.10+3.29%83

PBHPrestige Consumer Healthcare Inc.

$53.28+7.55%48

ALKSAlkermes plc

$45.90+0.46%36

Held by ETFs

INDV is in 96 US ETFs. The largest of them, with INDV's weight in each:

Spot a number that looks wrong? Check it in INDV's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing INDV

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.